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     The human scavenger receptor B1 (hSR-B1/CLA) is a HDL receptor with various anti-atherogenic 
functions which is expressed on the platelet surface. The anti thrombotic function of HDL includes the 
modulation of platelet reactivity, coagulation, and endothelial function. The goal of this study is to detect the 
level of HDL receptor on platelets of CAD patients with atherosclerotic disease. Expressions of the hSRB1 
receptor on platelets of 31 CAD patients with atherosclerotic plaque and 20 healthy controls was detected 
using flow cytometry. Moreover, the lipid panel tests were assayed by Chemistry auto analyzer and 
compared with healthy controls. Our findings show that abundance of hSR-B1/CLA-1 was significantly 
reduced on the surface of platelets from CAD patients with atherosclerotic disease compared with healthy 
control (6/8 % vs. 13/6 %), (P <0,001). 
The HDL receptor (hSR-B1/CLA-1) expression on platelets inversely correlates with the risk of coronary 
heart disease.  Our findings suggest that determining the level of hSR-B1/CLA-1 on the platelets may be a 
useful laboratory marker for CAD investigation. 
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INTRODUCTION 
      Atherosclerosis is the major pathological 
factor which caused CAD and its thrombotic 
consequences are a progressive disease 
predominantly occurring in the large arteries. 
There is a strong correlation between 
hypercholesterolemia and developing 
atherosclerosis plaque [1-3]. The High density 
Lipoprotein (HDL) plays an important role as an 
anti atherosclerotic agent. This is largely due to 
HDL function as a cholesterol vehicle, where 
HDL promotes cholesterol efflux from lipid-laden 
macrophages and takes this cholesterol back to 
the liver for processing [3-7]. 
 Scavenger receptor B1 can induce cholesterol 
efflux by enabling HDL to bind cells and 
reorganize lipids within cholesterol-rich   domains  
in the plasma membrane [8]. Studies in both 
humans and animal models indicated that HDL 
inhibits platelet activation via actions of HDL on 
the endothelium which induced them to produce 
nitric oxide (NO) and prostacyclin and tissue 
factor.  On the other hand, down regulate the 
platelet-activating factor, such as: thromboxane 
A2, results in inhibits platelet aggregation [9-11].  
 Further understanding of signaling by SR-BI will 
optimize the capacity to harness the mechanisms 
of action of HDL–SR-BI for cardiovascular 
benefit [12-14]. The goal of this study is to detect 
the level of HDL receptor expression on platelets 
of CAD patients who have atherosclerotic plaque.    
MATERIALS AND METHODS  
Patients 
     31 CAD patients   including unstable angina, 
 




myocardial infarction and acute coronary 
syndrome who visited the cardiovascular clinic of 
Tajrish hospital (Tehran) during 2015-2016 were 
under study. The participants gave informed 
consent in accordance with the Deceleration of 
Helsinki.  Before preparation of any sample, the 
variations of plaque severity score (PSS) were 
measured using CT angiography which has been 
described by Pagali SR, et al [17]. It was ensured 
that all patients had atherosclerotic plaque for 
control group; samples from 20 healthy 
volunteers were collected. 
Platelet preparation 
      Platelets were isolated from 10 ml 
anticoagulant (acid-citrate-dextrose) blood of 
patients and controls. The platelet-rich plasma 
was fractionated by centrifugation at 200 g for 10 
minutes at room temperature.  
Flow Cytometric Analysis 
      Platelets were washed three times with wash 
buffer (PBS); they were next resuspended in 
FACS buffer (0.1% BSA in PBS) at a 
concentration of 10
7
 platelets/mL in the same 
buffer. The cells were then  incubated with 20 μL 
diluted (1:100)  Rabbit  anti-scavenging Receptor 
SRB1 antibody (abcam  company)  and put  in ice 
for 3 hours followed by exposure to 5μL fluoresce 
in (FITC)-conjugated Goat anti Rabbit IgG H & L 
antibody ( abcam ) (1: 50 dilution) in ice for 1 
hour. For controls, platelets     were        incubated  
merely with FITC-conjugated Goat anti Rabbit 
IgG H & L (FITC) antibody (abcam). For Platelet  
gating, the Platelets were incubated with 
phycoerythrin (PE) conjugated anti-CD61 
antibody (Dako). For platelets' maintenance, 
100μL fixative buffer (0.1% paraformaldehyde in 
PBS) added to PRP before flow ctometry 
analysis. Finally, the platelets were analyzed 
using flow cytometry (model PARTEC) with 
forward scatter 160 and side scatter 215. 
Biochemistry Assays 
      Lipid panel (cholesterol, triglyceride, HDL, 
LDL, HDL/LDL ratio) , liver enzymes(AST, 
ALT, LDH), heart enzymes(CPK, CK-MB) and 
troponin were also measured using auto-analyzer 
( model CA-180 FURUNO). 
Statistical analysis 
     All experiments were repeated three times and 
statistical analyses were performed with SPSS 
software (version 21), using Pearson product-
moment correlation coefficient test for correlation 




     Out of 31 patients, 21 were male and 10 were 
female with the the average age 61.5 SEM 9.5; 13 
of controls were male and 7 female, with the 
average age  of 56.8 _SEM 4.2.Table 1 
summarizes the clinical and laboratory features of 
CAD patients with atherosclerotic. The amount of 
plaque was quantified as mild (score of 1+), 
moderate (score of 2+), or severe (score of 3+)
 
Table 1. Summary of the Clinical Features of the CAD Patients 
 
No  








1 56 M 2 + 122 44 59 
2 52 M 2 + 177 125 33 
3 58 F 1 + 168 104 44 
4 50 M 1 + 90 112 39 
5 71 M 1 + 136 85 28 
6 56 M 2 + 232 146 54 
7 79 M 1 + 128 72 40 
8 58 M 2 + 135 77 34 
9 51 F 1 + 226 41 40 
10 65 F 1 + 155 63 63 
11 61 M 1 + 143 50 52 
12 65 M 1 + 141 74 54 
13 49 F 1 + 177 122 38 
14 59 F 1 + 137 50 55 
15 68 M 1 + 132 68 50 
 

















M indicates male; F, female; T-Chol, total 
cholesterol; LDL-C, LDL cholestrol; HDL-C, 
HDL cholesterol, Atherosclerotic plaque 






Figure  1.  The mean and SD of serum lipid panel: triglyceride (TG), Total cholesterol (CHOL), LDL-cholesterol (LDL) , HDL-
cholesterol (HDL) and LDL/HDL ratio (L/H R) in patients 
 
 
The   Flow cytometry analysis of hSR-B1/CLA-1 
receptors on the Surface of patients and controls 
were detected on CD61-positive platelets (figure 
2).  
 
16 66 F 1 + 222 140 50 
17 77 M 1 + 171 107 35 
18 51 M 1 + 140 64 48 
19 74 M 1 + 129 65 45 
20 61 M 1 + 130 55 53 
21 79 M 1 + 210 140 63 
22 51 F 1 + 129 40 46 
23 63 M 1 + 131 63 41 
24 67 M 1 + 110 45 39 
25 67 F 1 + 218 132 51 
26 46 M 1 + 135 70 43 
27 58 F 1 + 224 143 51 
28 64 M 1 + 173 97 41 
29 57 M 1 + 164 65 58 
30 62 M 1 + 189 67 39 
31 41 F 1 + 163 59 43 
Concentration 
       mg/dL 
Lipid panel 
 





Figure2. Flow cytometric analysis for surface expression of hSR-B1 receptor in human platelets with CD 61+ (A); the mean 
fluorescence intensity (MFI) of a patient as  6.2 % (Figure B 
 
 
Differential levels of hSR-B1on platelets from 
patients with atherosclerotic disease were 
compared with controls.  
A representative profile of hSR-B1surface 
expression on the platelets from a healthy 
individual was compared with that of a patient 
with atherosclerotic disease. The mean of hSR-B1 
levels of platelets from the patient was clearly 
decreased in comparison with healthy controls. 
Figure 3 shows the mean fluorescence intensity 
(MFI) of hSR-B1 expression, which are 6.84 % 
and 13.6 %   in patients and controls respectively.    
Our study shows that hSR-B1 expression in 
platelets is decreased in patients with 




Figure 3. The percentage of the mean of hSRB1 expression platelets’ patients (left): 6.84% and controls (right) : 13.66% by flow 
cytometry,   (  p <0,001). 
 
The results of the comparison between the level 
of platelet HDL receptors and serum lipid panel 
and serum enzymes show that platelet HDL 
receptor expression did not significantly correlate 
with plasma cholesterol, HDL, LDL, or 
triglycerides  and heart enzyme, but do have a 
significant correlation with troponin ( P < 0.049). 
The comparison between serum biochemical and 








Table 2. The relation between the expression of platelet HDL receptors and serum biochemical factors in patients with CAD 
The relation between HDL receptor  and 













     The scavenger receptor class B type 1 (SR-B1) 
is a multi-ligand receptor that has high affinity for 
HDL and can mediate the bi-directional exchange 
of lipids between bound HDL and cells like 
platelets and macrophages [8,15].  In this study, 
the expression of hSR-B1/CLA-1 in platelets of 
CAD patients was detected. The results show that 
the expression of hSR-B1 receptor was 
significantly diminished in patients (p<0,001) in 
flow cytometry.  SR-B1 is believed to play an 
important role as a docking receptor for HDL in 
connection with selective uptake of cholesterol 
esters. It is tempting to speculate that decreased 
levels of hSR-B1/CLA-1 in platelets, isolated 
from patients with atherosclerotic disease, reflect 
a decrease in RCT and thus enhance their risk for 
developing the disease [14, 16]  . It could be said 
that the SR-BI as a HDL receptor has 




     These findings raise the possibility that a 
measurement of the hSR-B1/CLA-1 expression 
on human platelets may provide a valuable insight 
that reflects the status of RCT in patients with 
atherosclerosis and can show the risk of 
cardiovascular disease in future.  
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